LegislativeLabs.ai Logo
Legislative Labs
  • Bring the Statehouse to your House.
    • FAQ

      Help using Legislative Labs
    • Support

      Contact us for assistance.
    • Legal

      Terms & Conditions.
    • Privacy

      What we do with your information.
    • Choose Your Plan

      Track, Act, Learn.
    • Analytics

      Intelligence & analytics on previous sessions.
    • Bill History

      Detailed historical bill information.
    • Sponsor Detail

      Detailed sponsor bill performance.
    • About Us

      The reason for Legislative Labs.
    • Classroom

      Bring the Statehouse to the Schoolhouse.
    • BETA

      Session Dashboard

      Live predictions on introduced legislation.
    • BETA

      Bill Drafting

      Predictions on draft legislation.
    • BETA

      Legitron AI

      Legislation made simple with AI.
    • Session Results

      Legislative session analytics.
    • Sign in

HB 1674

Momentum Bucket Early Stage
Legal Title AN ACT Relating to hepatitis B and hepatitis C screening;
Bill Description Concerning hepatitis B and hepatitis C screening.
What this bill does
Powered by Legitron
This bill creates a new section in chapter 70.54 RCW that requires adult patients receiving primary care to be offered hepatitis B and hepatitis C screening tests during an annual physical, wellness visit, or the patient’s first visit with a provider new to the patient, using the latest CDC screening indications. Health care entities may comply by offering tests at those visits, adding electronic health record prompts for recommended populations, or sending routine mailers/electronic communications. Screenings must be offered in a culturally and linguistically appropriate manner. If a hepatitis B surface antigen test is positive, the provider must offer follow-up health care or refer the patient to another provider who can provide follow-up care. If a hepatitis C screening test is positive, the provider must offer follow-up health care or refer the patient and the follow-up must include a hepatitis C diagnostic test. The bill defines “follow-up health care” to include medical management and antiviral treatment for chronic hepatitis B or hepatitis C according to the latest AASLD clinical practice guidelines. Exceptions to the offering requirement are a life‑threatening emergency, the patient already having been offered or having had the test (unless the provider chooses to offer again), or the patient lacking capacity to consent. The measure also requires primary care providers to complete University of Washington online hepatitis B and C training modules by January 1, 2026, and requires providers licensed or new to primary care after that date to complete the training before providing primary care. The Department of Health may adopt rules to implement the section. The statute expressly does not change scope of practice or diminish provider authority and states that failure to comply does not subject a provider or primary care entity to licensure or certification actions or civil or criminal liability for that failure. Affected parties named include primary care providers and the health care entities where primary care is provided (including unlicensed clinics and urgent care clinics), adult patients, the University of Washington (training modules), and the Washington State Department of Health. Several details are not provided in the extracted text: an exact RCW subsection citation for the new section, a definition of “adult patient,” precise criteria for which providers must complete the UW training, how CDC screening indications are to be identified or updated, content or accreditation details for the training modules, who pays for tests or follow-up care, and any enforcement, monitoring, or reporting mechanisms beyond DOH rulemaking.
Why it matters
Powered by Legitron
If enacted, primary care clinics, urgent care centers, and the providers who work in them will be expected to offer hepatitis B and hepatitis C screening to adult patients during annual physicals, wellness visits, or a patient's first visit with a new provider using the latest CDC screening guidance, and to arrange or provide follow-up care (including a diagnostic HCV test) when results are positive. Providers must also complete University of Washington online hepatitis B and C training by January 1, 2026 (and new primary care providers must finish the training before they start), and the screenings and communications must be delivered in culturally and linguistically appropriate ways. That will create new front‑line responsibilities and likely added costs for clinics and providers — training time, staff time to offer tests and arrange referrals, and expenses for outreach or translated materials — though the bill does not say who pays for testing, diagnostics, or treatment. There is limited enforcement: failure to comply does not by itself trigger licensing or civil/criminal penalties, and the Department of Health can write implementing rules later, so some operational details and who ultimately bears costs or how CDC screening updates are applied remain unclear.
Official Documents View Full Bill Text
Follow this bill

HB 1674 Position - A premium account is required to save position information.

Saving your position first...
Generating hearing testimony using your position and notes...
Generating Bill Comment using your position and notes...

Click to view plans

HB 1674 Details and Bill Topics

Details

Date Introduced 01/28/2025
Originating Chamber House
Biennium 2025-26
Total Campaign Dollars Backing Bill $1,318,795.75

Bill Topics

HEALTH CARE

HB 1674 Sponsors and Committee Hearings

Sponsors

Representative Thai (Primary)
Representative Reed
Representative Scott
Representative Parshley
Representative Zahn
Representative Macri

Committee Hearings

Go to HB 1674 at leg.wa.gov

HB 1674 Bill Timeline

Early Stage
1/11/2026
HHC/Wellness
By resolution, reintroduced and retained in present status.
1/27/2025
HHC/Wellness
First reading, referred to Health Care & Wellness.

You have 3 pending action.

Legitron™ is a trademark of Legislative Labs, Inc.

© 2026 - Legislative Labs